AmberGen awarded Phase I SBIR grant from NIH-NCI IMAT program to develop PC-PURE™ for the detection of serological ovarian cancer biomarkers
/in News /by Annmarie ThompsonPaper published in Nature’s Scientific Reports “Proteome-wide drug screening using mass spectrometric imaging of bead-arrays” describing drug-discovery application of Bead-AMS™ including detection of on- and off-target drug binding
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonAmberGen receives US Patent 9,334,530 for its Bead-AMS™ technology describing synchronization of mass spectrometric and fluorescence images of mass-tagged bead arrays
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonJohn Gillespie, former Director of R&D for 3 Johnson & Johnson businesses including their multi-billion dollar Ethicon Products business, joins AmberGen as VP of Product and Business Development
/in MAKING A DIFFERENCE, News /by Annmarie ThompsonPaper published in Liver International “Anti-Kelch-like 12 and Anti-Hexokinase 1: Novel Autoantibodies in Primary Biliary Cirrhosis” resulting from a collaboration between AmberGen, INOVA Diagnostics and MGH
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonAmberGen receives US Patent 8,932,879 for its pioneering PC-PRINT™ technology
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonAmberGen receives US Patent 8,906,700 providing broad coverage on PC-PURE™ technology for biomarker isolation and use in highly sensitive and quantitative assays
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonAmberGen and Massachusetts General Hospital (MGH) are awarded US Patent 8,852,956 for two new diagnostic autoantigen biomarkers for the autoimmune liver disease Primary Biliary Cirrhosis (PBC)
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonAmberGen awarded 2-year Phase II SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions
/in News /by Annmarie ThompsonMenu
Menu 2
Recent News
- AmberGen announces that Dr. Michael Easterling, PhD will join Board of Directors
- AmberGen Announces New Appointments for John Gillespie & Dr. Kenneth J. Rothschild
- AmberGen and Bruker Collaborate on Spatial Biology Imaging Reagents for MALDI-Immunohistochemistry (MALDI-IHC)
- Dr. Mark Lim of AmberGen was honored to be an invited keynote speaker at the “Innovation in Mass Spectrometry Imaging Omics” Session